Osteoporosis and fractures: Diagnosis and management

Practice Nurse

Volumn 45, Issue 5, 2015, Pages

  Carne, Kirsty ^a  

^a NATIONAL OSTEOPOROSIS SOCIETY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85028038287     PISSN: 09536612     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (15)

1. British Orthopaedic Association. The Care of Patients with Fragility Fracture. London: British Orthopaedic Association.2007.
2. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. Geneva, World Health Organization, 1994 (WHO Technical Report Series, No. 843)
3. National Institute for Health and Care Excellence (NICE). Short Clinical Guideline (CG146) Assessing the risk of fragility fractures in osteoporosis. August 2012 https://www.nice.org.uk/guidance/cg146
4. Scottish Intercollegiate Guidelines Network (SIGN) Management of Osteoporosis. Guideline No 71. June 2003. Updated April 2004. Currently being updated. http://www.sign.ac.uk/guidelines/fulltext/71/
5. National Osteoporosis Guideline Group (NOGG). Osteoporosis clinical guideline for the prevention and treatment. Executive summary 2008, updated 2014. www.shef.ac.uk/NOGG/NOGG-Executive-Summary.pdf
6. NICE. Technology appraisal guidance TA 160. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the primary prevention of osteoporotic fragility fractures in postmenopausal women. January 2011. http://www.nice.org.uk/guidance/ta160
7. NICE. Technology appraisal guidance TA 161. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. January 2011. http://www.nice.org.uk/guidance/ta1601
8. NICE. Technology appraisal guidance TA 204.Denosumab for the prevention of osteoporotic fractures in postmenopausal women. October 2010. http://www.nice.org.uk/guidance/ta204
9. Weycker D, Macarios D, Edelsberg J, et al. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporosis International 2006;17:1645-52.
10. Kamatari M, Koto S, Ozawa N, et al. Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. Journal of Bone and Mineral Metabolism 2007;25(5):302-309.
11. Khosla S, Burr D, Cauley J et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research 2007 Oct;22(10):1479-91.
12. Bolland MJ, Grey A, Avenell, A, et al. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 2011;342:d2040
13. Medicines and Healthcare Products Regulatory Agency. Drug safety update. Bisphosphonates: atypical femoral fractures. June 2011. https://www.gov.uk/drug-safety-update/bisphosphonates-atypical-femoral-fractures
14. National Hip Fracture Database. National Hip Fracture Database (NHFD) extended report 2014. London: Royal College of Physicians.2014.
15. National Osteoporosis Society. Life with Osteoporosis: the untold story. 2014 Available at: https://www.nos.org.uk/document.doc?id=1715.